TEVA Q4 2025 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$37B

Q4 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.7B+11.4% YoY

Gross Profit

$2.7B56.4% margin

Operating Income

$300M6.4% margin

Net Income

$480M10.2% margin

EPS (Diluted)

$0.41

QoQ Revenue Growth

+5.2%

Cash Flow

Operating Cash Flow

$1.2B

Free Cash Flow

$1.0B

Stock-Based Comp.

$51M

Balance Sheet

Total Assets

$40.7B

Total Liabilities

$32.8B

Stockholders' Equity

$7.9B

Cash & Equivalents

$3.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.7B	$4.2B	+11.4%
Gross Profit	$2.7B	$2.1B	+25.3%
Operating Income	$300M	-$29M	+1134.5%
Net Income	$480M	-$217M	+321.2%

Revenue Segments

Product

$3.7B78%

License

$550M12%

Distribution Service

$384M8%

Product and Service, Other

$109M2%

Geographic Segments

United States Segment

$4.6B71%

Europe Segment

$1.3B21%

International Markets

$528M8%